NAS
OCUL icon

Nykredit A/S’s Ocular Therapeutix OCUL Stock Holding History

Nykredit A/S’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19K Buy
+1,931
New +$17.5K ﹤0.01% 1747

Other funds holding OCUL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Nykredit A/S's OCUL Position: Q2 2026 in Review

Nykredit A/S opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 1,931 shares worth $19K. The stake represents ﹤0.01% of the portfolio and ranks #1747 among its holdings.

170 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Nykredit A/S held 1,931 shares of Ocular Therapeutix worth $19K as of Q2 2026.
  • Ocular Therapeutix was a new Nykredit A/S position in Q2 2026.
  • Ocular Therapeutix made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1747 holding.
  • 170 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.